Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) scores 32 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is $1567.99, representing a 14833% margin of safety. Quantitative score: 50/100. Qualitative score: 20/100.

Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.

View full DMAA analysis on boothcheck